Technetium-99m methoxyisobutylisonitrile chest imaging for small-cell lung cancer. Relationship to chemotherapy response (six courses of combination of cisplatin and etoposide) and p-glycoprotein or multidrug resistance related protein expression

A. Kao, S. C. Shiun, N. Y. Hsu, S. S. Sun, C. C. Lee, C. C. Lin

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Aims: This is a retrospective and adaptive randomization study. The purpose of this study was to evaluate the relationship between technetium-99m methoxyisobutylisonitrile (Tc-99m MIBI) chest-imaging results, chemotherapy response and P-glycoprotein (Pgp) or multidrug resistance related protein (MRP) expression in small-cell lung cancer (SCLC). Patients and methods: Before chemotherapy, 30 patients (11 females, 19 males, ages: 52-69 years) with SCLC, including 14 extensive diseases without localized problems and 16 limited diseases in excess of solitary pulmonary nodule, underwent early chest imaging, including visual interpretation and quantitative analyses of tumor uptake ratio (TUR), 10 minutes after intravenous injection of Tc-99m MIBI. Immunohistochemical analyses were performed, using multiple nonconsecutive sections of the biopsy specimens, to detect Pgp and MRP expressions. Chemotherapy response was evaluated in the third month after completion of treatment by clinical and radiological methods. Results: All 15 (100%) of the SCLC patients with complete or partial response had positive Tc-99m MIBI chest SPECT results, but negative ones for both Pgp and MRP expression. Twelve of the 15 (80%) SCLC patients with no response or progressive disease had negative Tc-99m MIBI chest SPECT results and were positive for either Pgp or MRP expression (P <0.05). Negative Tc-99m MIBI chest SPECT results predicted complete or partial response. The TUR of patients with complete or partial response (1.91 ± 0.29 with a 95% confidence interval (95% CI): 1.75-2.07) was significantly higher than that of patients with no response or progressive disease (1.19 ± 0.28 with a 95% CI: 1.04-1.35). Conclusion: Tc-99m MIBI chest images are a potential tool for understanding Pgp and MRP expressions in SCLC and for predicting patient chemotherapy response.

Original languageEnglish
Pages (from-to)1561-1566
Number of pages6
JournalAnnals of Oncology
Volume12
Issue number11
DOIs
Publication statusPublished - 2001
Externally publishedYes

Fingerprint

P-Glycoproteins
Small Cell Lung Carcinoma
Etoposide
Cisplatin
Glycoproteins
Thorax
P-Glycoprotein
Drug Therapy
Single-Photon Emission-Computed Tomography
Solitary Pulmonary Nodule
Confidence Intervals
Random Allocation
technetium 99m methoxyisobutylisonitrile
Intravenous Injections
Neoplasms
Biopsy

Keywords

  • Chemotherapy
  • Multidrug resistance related protein
  • P-glycoprotein
  • Small-cell lung cancer
  • Technetium-99m methoxyisobutylisonitrile

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{b6334aa5fdbb446586426d63fb8aff80,
title = "Technetium-99m methoxyisobutylisonitrile chest imaging for small-cell lung cancer. Relationship to chemotherapy response (six courses of combination of cisplatin and etoposide) and p-glycoprotein or multidrug resistance related protein expression",
abstract = "Aims: This is a retrospective and adaptive randomization study. The purpose of this study was to evaluate the relationship between technetium-99m methoxyisobutylisonitrile (Tc-99m MIBI) chest-imaging results, chemotherapy response and P-glycoprotein (Pgp) or multidrug resistance related protein (MRP) expression in small-cell lung cancer (SCLC). Patients and methods: Before chemotherapy, 30 patients (11 females, 19 males, ages: 52-69 years) with SCLC, including 14 extensive diseases without localized problems and 16 limited diseases in excess of solitary pulmonary nodule, underwent early chest imaging, including visual interpretation and quantitative analyses of tumor uptake ratio (TUR), 10 minutes after intravenous injection of Tc-99m MIBI. Immunohistochemical analyses were performed, using multiple nonconsecutive sections of the biopsy specimens, to detect Pgp and MRP expressions. Chemotherapy response was evaluated in the third month after completion of treatment by clinical and radiological methods. Results: All 15 (100{\%}) of the SCLC patients with complete or partial response had positive Tc-99m MIBI chest SPECT results, but negative ones for both Pgp and MRP expression. Twelve of the 15 (80{\%}) SCLC patients with no response or progressive disease had negative Tc-99m MIBI chest SPECT results and were positive for either Pgp or MRP expression (P <0.05). Negative Tc-99m MIBI chest SPECT results predicted complete or partial response. The TUR of patients with complete or partial response (1.91 ± 0.29 with a 95{\%} confidence interval (95{\%} CI): 1.75-2.07) was significantly higher than that of patients with no response or progressive disease (1.19 ± 0.28 with a 95{\%} CI: 1.04-1.35). Conclusion: Tc-99m MIBI chest images are a potential tool for understanding Pgp and MRP expressions in SCLC and for predicting patient chemotherapy response.",
keywords = "Chemotherapy, Multidrug resistance related protein, P-glycoprotein, Small-cell lung cancer, Technetium-99m methoxyisobutylisonitrile",
author = "A. Kao and Shiun, {S. C.} and Hsu, {N. Y.} and Sun, {S. S.} and Lee, {C. C.} and Lin, {C. C.}",
year = "2001",
doi = "10.1023/A:1013133801173",
language = "English",
volume = "12",
pages = "1561--1566",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Technetium-99m methoxyisobutylisonitrile chest imaging for small-cell lung cancer. Relationship to chemotherapy response (six courses of combination of cisplatin and etoposide) and p-glycoprotein or multidrug resistance related protein expression

AU - Kao, A.

AU - Shiun, S. C.

AU - Hsu, N. Y.

AU - Sun, S. S.

AU - Lee, C. C.

AU - Lin, C. C.

PY - 2001

Y1 - 2001

N2 - Aims: This is a retrospective and adaptive randomization study. The purpose of this study was to evaluate the relationship between technetium-99m methoxyisobutylisonitrile (Tc-99m MIBI) chest-imaging results, chemotherapy response and P-glycoprotein (Pgp) or multidrug resistance related protein (MRP) expression in small-cell lung cancer (SCLC). Patients and methods: Before chemotherapy, 30 patients (11 females, 19 males, ages: 52-69 years) with SCLC, including 14 extensive diseases without localized problems and 16 limited diseases in excess of solitary pulmonary nodule, underwent early chest imaging, including visual interpretation and quantitative analyses of tumor uptake ratio (TUR), 10 minutes after intravenous injection of Tc-99m MIBI. Immunohistochemical analyses were performed, using multiple nonconsecutive sections of the biopsy specimens, to detect Pgp and MRP expressions. Chemotherapy response was evaluated in the third month after completion of treatment by clinical and radiological methods. Results: All 15 (100%) of the SCLC patients with complete or partial response had positive Tc-99m MIBI chest SPECT results, but negative ones for both Pgp and MRP expression. Twelve of the 15 (80%) SCLC patients with no response or progressive disease had negative Tc-99m MIBI chest SPECT results and were positive for either Pgp or MRP expression (P <0.05). Negative Tc-99m MIBI chest SPECT results predicted complete or partial response. The TUR of patients with complete or partial response (1.91 ± 0.29 with a 95% confidence interval (95% CI): 1.75-2.07) was significantly higher than that of patients with no response or progressive disease (1.19 ± 0.28 with a 95% CI: 1.04-1.35). Conclusion: Tc-99m MIBI chest images are a potential tool for understanding Pgp and MRP expressions in SCLC and for predicting patient chemotherapy response.

AB - Aims: This is a retrospective and adaptive randomization study. The purpose of this study was to evaluate the relationship between technetium-99m methoxyisobutylisonitrile (Tc-99m MIBI) chest-imaging results, chemotherapy response and P-glycoprotein (Pgp) or multidrug resistance related protein (MRP) expression in small-cell lung cancer (SCLC). Patients and methods: Before chemotherapy, 30 patients (11 females, 19 males, ages: 52-69 years) with SCLC, including 14 extensive diseases without localized problems and 16 limited diseases in excess of solitary pulmonary nodule, underwent early chest imaging, including visual interpretation and quantitative analyses of tumor uptake ratio (TUR), 10 minutes after intravenous injection of Tc-99m MIBI. Immunohistochemical analyses were performed, using multiple nonconsecutive sections of the biopsy specimens, to detect Pgp and MRP expressions. Chemotherapy response was evaluated in the third month after completion of treatment by clinical and radiological methods. Results: All 15 (100%) of the SCLC patients with complete or partial response had positive Tc-99m MIBI chest SPECT results, but negative ones for both Pgp and MRP expression. Twelve of the 15 (80%) SCLC patients with no response or progressive disease had negative Tc-99m MIBI chest SPECT results and were positive for either Pgp or MRP expression (P <0.05). Negative Tc-99m MIBI chest SPECT results predicted complete or partial response. The TUR of patients with complete or partial response (1.91 ± 0.29 with a 95% confidence interval (95% CI): 1.75-2.07) was significantly higher than that of patients with no response or progressive disease (1.19 ± 0.28 with a 95% CI: 1.04-1.35). Conclusion: Tc-99m MIBI chest images are a potential tool for understanding Pgp and MRP expressions in SCLC and for predicting patient chemotherapy response.

KW - Chemotherapy

KW - Multidrug resistance related protein

KW - P-glycoprotein

KW - Small-cell lung cancer

KW - Technetium-99m methoxyisobutylisonitrile

UR - http://www.scopus.com/inward/record.url?scp=0035692579&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035692579&partnerID=8YFLogxK

U2 - 10.1023/A:1013133801173

DO - 10.1023/A:1013133801173

M3 - Article

VL - 12

SP - 1561

EP - 1566

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 11

ER -